ClinicalTrials.gg
CompletedNCT01877915COMMANDER HFUpdated May 10, 2019Results posted

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

A Phase 3 interventional study of Rivaroxaban and Placebo in Heart Failure and Coronary Artery Disease, sponsored by Janssen Research & Development, LLC. Completed at 578 sites in 32 countries. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2019-05-10.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,081
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Heart Failure by Johnson & Johnson — 3 open to participants now, 5 under way, none of them phase 3. Heart Failure · Johnson & Johnson.

Enrollment
3rd of 33
5,081 · median 91
Started
2013
with 1 other
Phase 3
12 of 42
none open now
Registered
26th of 42
by date

Among the 42 studies in Heart Failure by Johnson & Johnson, this one is the 3rd largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2013, is one of 12 in phase 3, and was the 26th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

3 of the 42 studies in Heart Failure by Johnson & Johnson are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Heart Failure by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure.

Read the detailed description

This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), parallel group (each participant group receives different treatments simultaneously), event driven (the study duration is determined by the time taken for a specific number of events to occur), multicenter study to assess the effectiveness and safety of rivaroxaban compared with placebo, in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure. Participants will be randomly assigned in a 1:1 ratio to receive either rivaroxaban or placebo (each in addition to standard of care for heart failure and coronary artery disease as prescribed by their managing physician). The study will consist of a screening phase, a double-blind treatment phase, and a follow-up after the sponsor-announced global treatment end date (GTED, defined as the date when 1200 primary efficacy outcome events are predicted to have occurred). The double-blind treatment phase is estimated to last for 6 to 54 months. Participants will discontinue study drug after taking both their morning and evening doses on the GTED and will return to the study center for the end-of-study visit (between 15 and 45 days but no sooner than 15 days after the GTED). Patient safety will be monitored throughout the study. The average study duration for participants is expected to be approximately 29 months. The study drug, rivaroxaban, is approved in the United States and in multiple countries around the world for the prevention and treatment of a number of thrombosis-mediated conditions.

03

Conditions studied

  • Heart Failure
  • Coronary Artery Disease

Keywords

  • Heart Failure
  • Coronary Artery Disease
  • Stroke
  • Myocardial Infarction
  • Anticoagulation
04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have symptomatic heart failure for at least 3 months prior to Screening
  • Participants must have an episode of decompensated heart failure (index event) requiring (a) an overnight stay [that is, staying past midnight] in a hospital, emergency department, or medical facility with the capability of treating with intravenous medications and observing heart failure patients before randomization or (b) an unscheduled outpatient visit to a heart failure management center, where parenteral therapy is required for heart failure stabilization. An episode of decompensated heart failure is defined as symptoms of worsening dyspnea or fatigue, objective signs of congestion such as peripheral edema or ascites, and/or adjustment of pre-hospitalization/outpatient visit heart failure medications. Participants are eligible for randomization at discharge from the facility treating the index event and up to 30 days after discharge if they are in stable condition
  • Must have a documented (LVEF) of less than or equal to 40 percent (%) within 1 year before randomization
  • Must have evidence of significant coronary artery disease
  • Must be medically stable in terms of their heart failure clinical status at the time of randomization
  • Must have a brain natriuretic peptide (BNP) level greater than or equal to (>=) 200 picogram per milliliter (pg/mL) or N-terminal-proBNP (NT-proBNP) level >=800 pg/mL (preferred assay) during the Screening period and before randomization

Exclusion criteria

Exclusion Criteria:

  • Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding, such as, but not limited to, active internal bleeding, bleeding, bleeding at a noncompressible site, or bleeding diathesis within 28 days of randomization
  • Severe concomitant disease such as (a) atrial fibrillation (AFib) or another condition that requires chronic anticoagulation (participants with isolated transient AFib may be allowed at the discretion of the treating physician investigator) and (b) Documented acute myocardial infarction (MI) during index event
  • Prior stroke within 90 days of randomization
  • Has been hospitalized for longer than 21 days during the index event
  • Planned intermittent outpatient treatment with positive inotropic drugs administered intravenously
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5,081 participants (actual)

Study arms

  • Experimental
    Rivaroxaban 2.5 mg

    Each participant will receive 2.5 mg of rivaroxaban twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).

    Drug: Rivaroxaban · Other: Standard of care for heart failure and coronary artery disease

  • Placebo comparator
    Placebo

    Each participant will receive matching placebo twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).

    Drug: Placebo · Other: Standard of care for heart failure and coronary artery disease

Interventions

  • Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).

  • DrugPlacebo

    Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).

  • OtherStandard of care for heart failure and coronary artery disease

    Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.

06

What researchers measure

Primary outcomes

  1. Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke

    Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient \[pt\]-year \[yr\]) = 100\*n/(total risk exposure), where n is the number of events.

    Time frame: Up to Global treatment end date (approximately 54 months)

  2. Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability

    Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

    Time frame: Up to 227 Weeks

Secondary outcomes

  1. Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF)

    Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

    Time frame: Up to Global treatment end date (approximately 54 months)

  2. Event Rate of Cardio Vascular Death

    Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

    Time frame: Up to Global treatment end date (approximately 54 months)

  3. Event Rate of Re-Hospitalization for Worsening of Heart Failure

    Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

    Time frame: Up to Global treatment end date (approximately 54 months)

  4. Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV)

    Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

    Time frame: Up to Global treatment end date (approximately 54 months)

  5. Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure

    Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

    Time frame: Up to Global treatment end date (approximately 54 months)

  6. Event Rate of Bleeding Events That Requiring Hospitalization

    Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

    Time frame: Up to 227 Weeks

  7. Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event

    Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

    Time frame: Up to 227 Weeks

07

Results

Posted May 10, 2019

Participant flow

Participant flow — Overall Study
MilestoneRivaroxabanPlacebo
Started25072515
Completed24532447
Not completed5468
Withdrew: Lost to follow-up109
Withdrew: Withdrawal by subject4255
Withdrew: Other24

Outcome measures

PrimaryEvent Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke

Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient \[pt\]-year \[yr\]) = 100\*n/(total risk exposure), where n is the number of events.

Time frame:
Up to Global treatment end date (approximately 54 months)
Reported as:
Number · Event rate per 100 patient-year
Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke
Event rate per 100 patient-yearRivaroxabanPlacebo
Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke13.4414.27
Statistical analysis
  • Rivaroxaban vs Placebo · Log Rank · p = 0.270 · Hazard ratio (hr): 0.94 · 95% CI 0.84 to 1.05
SecondaryEvent Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF)

Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

Time frame:
Up to Global treatment end date (approximately 54 months)
Reported as:
Number · Event rate per 100 patient-year
Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF)
Event rate per 100 patient-yearRivaroxabanPlacebo
Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF)23.3223.46
SecondaryEvent Rate of Cardio Vascular Death

Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

Time frame:
Up to Global treatment end date (approximately 54 months)
Reported as:
Number · Event rate per 100 patient-year
Event Rate of Cardio Vascular Death
Event rate per 100 patient-yearRivaroxabanPlacebo
Event Rate of Cardio Vascular Death9.469.96
SecondaryEvent Rate of Re-Hospitalization for Worsening of Heart Failure

Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

Time frame:
Up to Global treatment end date (approximately 54 months)
Reported as:
Number · Event rate per 100 patient-year
Event Rate of Re-Hospitalization for Worsening of Heart Failure
Event rate per 100 patient-yearRivaroxabanPlacebo
Event Rate of Re-Hospitalization for Worsening of Heart Failure17.2417.45
SecondaryEvent Rate of Re-Hospitalization for Cardio Vascular Events (RHCV)

Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

Time frame:
Up to Global treatment end date (approximately 54 months)
Reported as:
Number · Event rate per 100 patient-year
Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV)
Event rate per 100 patient-yearRivaroxabanPlacebo
Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV)13.3014.04
SecondaryEvent Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure

Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

Time frame:
Up to Global treatment end date (approximately 54 months)
Reported as:
Number · Event rate per 100 patient-year
Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure
Event rate per 100 patient-yearRivaroxabanPlacebo
Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure24.8424.57
PrimaryEvent Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability

Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

Time frame:
Up to 227 Weeks
Reported as:
Number · Event rate per 100 patient-year
Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability
Event rate per 100 patient-yearRivaroxabanPlacebo
Fatal Bleeding0.220.22
Critical Space Bleeding with Permanent Disability0.320.48
Statistical analysis
  • Rivaroxaban vs Placebo · Log Rank · p = 0.951 · Hazard ratio (hr): 1.03 · 95% CI 0.41 to 2.59
  • Rivaroxaban vs Placebo · Log Rank · p = 0.253 · Hazard ratio (hr): 0.67 · 95% CI 0.33 to 1.34
SecondaryEvent Rate of Bleeding Events That Requiring Hospitalization

Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

Time frame:
Up to 227 Weeks
Reported as:
Number · Event rate per 100 patient-year
Event Rate of Bleeding Events That Requiring Hospitalization
Event rate per 100 patient-yearRivaroxabanPlacebo
Event Rate of Bleeding Events That Requiring Hospitalization1.521.16
SecondaryEvent Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event

Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100\*n/(total risk exposure), where n is the number of events.

Time frame:
Up to 227 Weeks
Reported as:
Number · Event rate per 100 patient-year
Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event
Event rate per 100 patient-yearRivaroxabanPlacebo
Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event2.041.21

Adverse events

Collected over Up to 54 Months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban565/2,507 (22.5%)479/2,507 (19.1%)53/2,507 (2.1%)
Placebo571/2,515 (22.7%)451/2,515 (17.9%)60/2,515 (2.4%)
Most frequent serious events
Showing 10 of 523
Most frequent serious events
EventRivaroxabanPlacebo
PneumoniaInfections and infestations68/250772/2515
Acute Kidney InjuryRenal and urinary disorders17/250728/2515
SepsisInfections and infestations16/25077/2515
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders15/250716/2515
Urinary Tract InfectionInfections and infestations14/25079/2515
Chronic Kidney DiseaseRenal and urinary disorders14/25077/2515
AnaemiaBlood and lymphatic system disorders12/25077/2515
BronchitisInfections and infestations12/25079/2515
Renal FailureRenal and urinary disorders12/250712/2515
CholecystitisHepatobiliary disorders10/25075/2515
Most frequent other events
Most frequent other events
EventRivaroxabanPlacebo
NasopharyngitisInfections and infestations53/250760/2515

Baseline characteristics

Age, Continuous
Age, Continuous(years)RivaroxabanPlaceboTotal
Mean66.5 ± 10.0766.3 ± 10.2766.4 ± 10.17
Sex: Female, Male
Sex: Female, Male(Participants)RivaroxabanPlaceboTotal
Female5515991150
Male195619163872
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RivaroxabanPlaceboTotal
Hispanic or Latino309300609
Not Hispanic or Latino218622034389
Unknown or Not Reported121224
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RivaroxabanPlaceboTotal
American Indian or Alaska Native111021
Asian362365727
Native Hawaiian or Other Pacific Islander202
Black or African American293665
White206320654128
More than one race459
Unknown or Not Reported363470
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RivaroxabanPlaceboTotal
Asian362365727
Black or African American293665
Other5956115
White Hispanic or Latino258251509
White Non-Hispanic179918073606
Region of Enrollment
Region of Enrollment(Participants)RivaroxabanPlaceboTotal
ARGENTINA7676152
AUSTRALIA7714
BRAZIL8080160
BULGARIA314314628
CANADA141428
CHINA186186372
CZECH REPUBLIC353469
DENMARK9918
FRANCE101020
GERMANY323264
GREECE8816
HUNGARY6969138
ITALY353671
JAPAN133132265
LATVIA121325
LITHUANIA171835
MALAYSIA171734
MEXICO7373146
NETHERLANDS123
POLAND288290578
PORTUGAL202242
ROMANIA200198398
RUSSIAN FEDERATION274276550
SLOVAKIA414182
SOUTH AFRICA8816
SOUTH KOREA242448
SPAIN8989178
SWEDEN235
TURKEY9696192
UKRAINE264265529
UNITED KINGDOM131225
UNITED STATES6061121
08

Study locations

578 sites
  • Alexander City, Alabama, United States
  • Birmingham, Alabama, United States
  • Mobile, Alabama, United States
  • Anchorage, Alaska, United States
  • Tucson, Arizona, United States
  • Jonesboro, Arkansas, United States
  • Beverly Hills, California, United States
  • Chula Vista, California, United States
  • El Cajon, California, United States
  • Glendale, California, United States
  • La Mesa, California, United States
  • Los Angeles, California, United States
  • Newport Beach, California, United States
  • Orange, California, United States
  • Stockton, California, United States
  • Torrance, California, United States
  • Aurora, Colorado, United States
  • Denver, Colorado, United States
  • New Haven, Connecticut, United States
  • Atlantis, Florida, United States
  • Daytona Beach, Florida, United States
  • Jupiter, Florida, United States
  • Orlando, Florida, United States
  • Saint Petersburg, Florida, United States
  • Tallahassee, Florida, United States
  • Wellington, Florida, United States
  • Winter Haven, Florida, United States
  • Athens, Georgia, United States
  • Atlanta, Georgia, United States
  • Cumming, Georgia, United States
  • Macon, Georgia, United States
  • Tucker, Georgia, United States
  • Chicago, Illinois, United States
  • Evanston, Illinois, United States
  • Fairview Heights, Illinois, United States
  • Peoria, Illinois, United States
  • Rockford, Illinois, United States
  • Urbana, Illinois, United States
  • Anderson, Indiana, United States
  • Indianapolis, Indiana, United States
  • Merrillville, Indiana, United States
  • Munster, Indiana, United States
  • South Bend, Indiana, United States
  • Iowa City, Iowa, United States
  • Elizabethtown, Kentucky, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Owensboro, Kentucky, United States
  • Bossier City, Louisiana, United States
  • Hammond, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Slidell, Louisiana, United States
  • Biddeford, Maine, United States
  • Baltimore, Maryland, United States
  • Columbia, Maryland, United States
  • Randallstown, Maryland, United States
  • Bay City, Michigan, United States
  • Grand Blanc, Michigan, United States
  • Mount Clemens, Michigan, United States
  • Pontiac, Michigan, United States
  • Ypsilanti, Michigan, United States
  • Saint Paul, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Springfield, Missouri, United States
  • Washington, Missouri, United States
  • Lincoln, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Bridgewater, New Jersey, United States
  • Elmer, New Jersey, United States
  • Haddon Heights, New Jersey, United States
  • Manalapan, New Jersey, United States
  • Ridgewood, New Jersey, United States
  • Sewell, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Buffalo, New York, United States
  • Cortlandt Manor, New York, United States
  • Jamaica, New York, United States
  • Mineola, New York, United States
  • New York, New York, United States
  • Charlotte, North Carolina, United States
  • High Point, North Carolina, United States
  • Pinehurst, North Carolina, United States
  • Canton, Ohio, United States
  • Cincinnati, Ohio, United States
  • Columbus, Ohio, United States
  • Dayton, Ohio, United States
  • Fairfield, Ohio, United States
  • Kettering, Ohio, United States
  • Bartlesville, Oklahoma, United States
  • Oklahoma City, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Portland, Oregon, United States
  • Doylestown, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Sayre, Pennsylvania, United States
  • Sellersville, Pennsylvania, United States
  • Wynnewood, Pennsylvania, United States
  • Yardley, Pennsylvania, United States
  • York, Pennsylvania, United States
  • Charleston, South Carolina, United States

Showing the first 100 of 578 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ferreira JP, Cleland JG, Lam CSP, Anker SD, Mehra MR, van Veldhuisen DJ, Byra WM, La Police DA, Pitt B, Greenberg B, Zannad F. Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE. Clin Res Cardiol. 2021 Oct;110(10):1554-1563. doi: 10.1007/s00392-021-01830-1. Epub 2021 Mar 8. PubMed 33686472 ↗
  • Ferreira JP, Cleland JGF, Lam CSP, van Veldhuisen DJ, Byra WM, La Police DA, Anker SD, Mehra MR, Leroy C, Eschwege V, Toussaint-Hacquard M, Rossignol P, Greenberg B, Zannad F. Impact of Geographic Region on the COMMANDER-HF Trial. JACC Heart Fail. 2021 Mar;9(3):201-211. doi: 10.1016/j.jchf.2020.11.007. Epub 2021 Feb 3. PubMed 33549557 ↗
  • Cunningham JW, Ferreira JP, Deng H, Anker SD, Byra WM, Cleland JGF, Gheorghiade M, Lam CSP, La Police D, Mehra MR, Neaton JD, Spiro TE, van Veldhuisen DJ, Greenberg B, Zannad F. Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF. JACC Heart Fail. 2020 May;8(5):359-368. doi: 10.1016/j.jchf.2019.12.009. Epub 2020 Mar 11. PubMed 32171760 ↗
  • Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF, Lam CSP, van Veldhuisen DJ, Byra WM, Spiro TE, Deng H, Zannad F, Greenberg B. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. Eur Heart J. 2019 Nov 21;40(44):3593-3602. doi: 10.1093/eurheartj/ehz427. PubMed 31461239 ↗
  • Greenberg B, Neaton JD, Anker SD, Byra WM, Cleland JGF, Deng H, Fu M, La Police DA, Lam CSP, Mehra MR, Nessel CC, Spiro TE, van Veldhuisen DJ, Vanden Boom CM, Zannad F. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. JAMA Cardiol. 2019 Jun 1;4(6):515-523. doi: 10.1001/jamacardio.2019.1049. PubMed 31017637 ↗
  • Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B; COMMANDER HF Investigators. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi: 10.1056/NEJMoa1808848. Epub 2018 Aug 27. PubMed 30146935 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Apr 2018, 55 months.

Results were first posted in May 2019, 1 year after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 55 months is above that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2013
First posted
Jun 14, 2013
StartActual
Sep 10, 2013
Primary completionActual
Apr 19, 2018
CompletionActual
Apr 19, 2018
Results first posted
May 10, 2019
Last update
May 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01877915
Collaborators
Bayer
Responsible party
Sponsor
First posted
Jun 14, 2013
Start date
Sep 10, 2013
Primary completion
Apr 19, 2018
Completion
Apr 19, 2018
Results posted
May 10, 2019
Last update
May 10, 2019

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion